Meningitis diagnostic testing comprises serological test results in patients who have a positive history of viral meningitis. Clinical diagnosis is quite limited in terms of when blood culture is used to determine the clinical diagnosis. In most cases, it is diagnosed clinically by viral serology testing on a patient with viral meningitis, followed by a blood culture from a cervical swab sample taken during the epidemic. Meningitis caused by a viral meningococcus infection, especially the Mumps virus, is the most common kind of meningitis. Acute meningitis, a bacterial infection, also causes acute inflammation and recurrent fever blisters on all portions of the body with characteristic rash and pain.
A positive viral culture is seen in the majority of patients with acute meningitis, which is confirmed by serum antibody titer and infected cerebellar tissue culture. Because the majority of cases of meningitis are caused by a single strain of meningococcus, confirming meningitis diagnostic tests with a culture of blood or other material from the throat, nose, and throat is important. Although a blood culture confirms a clinical diagnosis of viral meningitis, there are rare cases of meningitis caused by bacteria strains such as Streptococcus pneumoniae and enteroviruses that can only be cultured in the laboratory.
Though a positive blood culture is an initial step toward diagnosis, it is not sufficient in all situations to establish meningitis diagnostic tests. In reality, in certain individuals, culture and positive serological test findings might lead to a viral meningitis diagnosis, and in such situations, viral meningitis is considered the predominant strain of meningitis. This is due to the high mortality rate of untreated acute meningitis; individuals with acute meningitis die within a few weeks after being diagnosed. As a result, appropriate therapy for these individuals is required to prevent the infection from rapidly spreading throughout the body. It is therefore imperative to control the mortality rate of acute meningitis and improve the morbidity rates.
Lumbar puncture is an important part of meningitis diagnostic testing. The goal of this operation is to decrease swelling and, as a result, relieve discomfort and strain on the spinal cord and discs. The doctor can do the lumbar puncture in one of two methods. The first involves inserting the needle into a smaller hole on the patient's back, injecting only a little amount of liquid. The doctor can also do the lumbar puncture by inserting the needle via the top of the leg or through the navel. The doctor will use a smaller needle and inject the fluid at a considerably faster rate in the first approach. By injecting a smaller amount of fluid at a slower rate, the doctor will be able to deliver a sufficient amount of medication to the body and reduce pain.
In 2017, the bacterial type dominated the global market, in terms of revenue.
Asia-Pacific is expected to be the fastest growing contributor to the global market revenue in 2017.Swelling to the meninges is known as meningitis.
Meningitis affects the meninges, the membranes that covers spinal cord and brain that protect the central nervous system (CNS) along with the cerebrospinal fluid.
Meningitis can cause by bacteria, fungal and virus.
Some of the bacteria that can cause bacterial meningitis are Group B Streptococcus and Streptococcus pneumoniae (S. pneumoniae).
However, the bacterial type is the most lethal which is considered as life-threatening type.Other factors causing meningitis are HIV, tuberculosis, and certain illness.
Global Meningitis Diagnosis and Treatment Market Size is expected to rise to a valuation of USD 430.2 million by 2023, rising at a solid 3.38% CAGR over the forecast period from 2018 to 2023.
The global Meningitis Diagnosis and Treatment Market Size is mainly driven by the growing prevalence of meningitis as well as the increasing efforts to combat the disease, including efforts to reduce the incidence of the disease as well as efforts to manage the disease better.Global Meningitis Diagnosis and Treatment Market Size Insights 2020 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making.
This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability.
It provides information on trends and developments, and focuses on Markets and materials, capacities and technologies, and on the changing structure of the Serotonin Supplements Market.Some of the key players operating for the global market analysis are B. Braun Melsungen AG, Sanofi, Pfizer Inc., Siemens Healthcare Private Limited, GlaxoSmithKline plc, Merck KGaA, Baxter, Abbott, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Luminex Corporation, F. Hoffman-La Roche Ltd., Cepheid, and Pfizer Inc.,Meningitis Diagnosis and Treatment Market Size Research Coverage:Changing market dynamics of the industryTo get a comprehensive overview of the Meningitis Diagnosis and Treatment Market Size.Historical, current and projected market size in terms of volume and valueIn-depth market segmentationCompetitive landscapeThe report presents an all-inclusive database in a systematic and highly comprehensive manner.
It intends to offer valid, factual, reliable, and easily understandable information about the which makes it more eloquent.
Our analysis team applies a tried and tested primary and secondary research methodology to provide accurate and indubitable findings.Chapters for This Meningitis Diagnosis and Treatment Market Size Study: -Chapter 1: Introduction, product scope, market overview, market opportunities, market risk, market driving force;Chapter 2: to analyse the top manufacturers of Global Market Size, with sales, revenue, and price.Chapter 3: to display the competitive situation among the top manufacturers, with sales, revenue and market share in Forecasted Time.Chapter 4: to show the Global Meningitis Diagnosis and Treatment Market Size by regions, with sales, revenue and market share for each region, during the forecast period.Chapter 5, 6, 7, 8 and 9: to analyse the key regions, with sales, revenue and market share by key countries in these regions;Chapter 10: to show the market by type and application, with sales market share and growth rate by type, application, Methodology, Analyst Introduction, Data Source By MRFRAccess Complete Detailed TOC Research Report at https://www.marketresearchfuture.com/reports/meningitis-diagnosis-and-treatment-market-5730This report focuses on the global Meningitis Diagnosis and Treatment Market Size status, future forecast, growth opportunity, key market and key players.
Global Meningitis Diagnosis and Treatment Market Research Report: by Type (Viral Meningitis, Bacterial Meningitis, and Others), by Treatment & Diagnosis (Treatment and Diagnosis), by End-user (Hospitals & Clinics, Others), and Region - Forecast till 2027Overview:The global meningitis diagnosis and treatment market can reach a size of USD 430.20 million by 2023, as per the latest report of Market Research Future (MRFR).
It is likely to register a CAGR of 3.38% from 2018 to 2023 (forecast period) due to rising prevalence of viral, bacterial, and fungal infections.
According to the National Health Council, increasing number of Americans likely to be affected by chronic diseases and it can touch 157 million by 2020.
Moreover, development of drugs for the treatment of meningitis can create opportunities for the market.Segmentation Analysis:The global meningitis diagnosis and treatment market is segmented by type, treatment & diagnosis, and end-user.By type, viral meningitis held 43.4% share in 2017, followed by bacterial meningitis, fungal meningitis, and others.
Bacterial meningitis is likely to register highest CAGR of 3.54% over the forecast period.By treatment & diagnosis, treatment accounted for noticeable market share in 2017, with diagnosis holding second place in the same year.
Presence of various players and rapid approval of drugs can positively impact the revenue margins of the meningitis and diagnosis treatment market.
